|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Samuel M, Chow PK, Chan Shih-Yen E, Machin
D and Soo KC: Neoadjuvant and adjuvant therapy for surgical
resection of hepatocellular carcinoma. Cochrane Database Syst Rev.
1:CD0011992009.PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhai B and Sun XY: Mechanisms of
resistance to sorafenib and the corresponding strategies in
hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berasain C: Hepatocellular carcinoma and
sorafenib: Too many resistance mechanisms? Gut. 62:1674–1675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rohwer N and Cramer T: Hypoxia-mediated
drug resistance: Novel insights on the functional interaction of
HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang Y, Zheng T, Song R, Wang J, Yin D,
Wang L, Liu H, Tian L, Fang X, Meng X, et al: Hypoxia-mediated
sorafenib resistance can be overcome by EF24 through Von
Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in
hepatocellular carcinoma. Hepatology. 57:1847–1857. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang YS, Adnane J, Trail PA, Levy J,
Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A,
et al: Sorafenib (BAY 43-9006) inhibits tumor growth and
vascularization and induces tumor apoptosis and hypoxia in RCC
xenograft models. Cancer Chemother Pharmacol. 59:561–574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamashita T, Ohneda K, Nagano M, Miyoshi
C, Kaneko N, Miwa Y, Yamamoto M, Ohneda O and Fujii-Kuriyama Y:
Hypoxia-inducible transcription factor-2alpha in endothelial cells
regulates tumor neovascularization through activation of ephrin A1.
J Biol Chem. 283:18926–18936. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Menrad H, Werno C, Schmid T, Copanaki E,
Deller T, Dehne N and Brüne B: Roles of hypoxia-inducible
factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of
hepatocellular tumor spheroids. Hepatology. 51:2183–2192. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo D, Wang Z and Wu J, Jiang C and Wu J:
The role of hypoxia inducible factor-1 in hepatocellular carcinoma.
BioMed Res Int. 2014:4092722014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin TY, Chou CF, Chung HY, Chiang CY, Li
CH, Wu JL, Lin HJ, Pai TW, Hu CH and Tzou WS: Hypoxia-inducible
factor 2 alpha is essential for hepatic outgrowth and functions via
the regulation of leg1 transcription in the zebrafish embryo. PLoS
One. 9:e1019802014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong X, Li R, Xiu P, Dong X, Xu Z, Zhai B,
Liu F, Jiang H, Sun X, Li J, et al: Meloxicam executes its
antitumor effects against hepatocellular carcinoma in
COX-2-dependent and -independent pathways. PLoS One. 9:e928642014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F,
Wei Z, Zhai B, Kanwar JR, Jiang H, et al: Secretory clusterin
contributes to oxaliplatin resistance by activating Akt pathway in
hepatocellular carcinoma. Cancer Sci. 104:375–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen H, Sun B, Pan S, Jiang H and Sun X:
Dihydroartemisinin inhibits growth of pancreatic cancer cells in
vitro and in vivo. Anticancer Drugs. 20:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang
X, Xie L, Jiang G, Li Q and Wang E: C-Myc participates in
β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma
cells. APMIS. 122:1251–1258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu H and Li Z, Yang P, Zhang L, Fan Y and
Li Z: PKM2 depletion induces the compensation of glutaminolysis
through β-catenin/c-Myc pathway in tumor cells. Cell Signal.
26:2397–2405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee KB, Ye S, Park MH, Park BH, Lee JS and
Kim SM: p63-Mediated activation of the β-catenin/c-Myc signaling
pathway stimulates esophageal squamous carcinoma cell invasion and
metastasis. Cancer Lett. 353:124–132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao D, Zhai B, He C, Tan G, Jiang X, Pan
S, Dong X, Wei Z, Ma L, Qiao H, et al: Upregulation of HIF-2α
induced by sorafenib contributes to the resistance by activating
the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell
Signal. 26:1030–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ
and Wu C: The correlation of expression levels of HIF-1α and HIF-2α
in hepatocellular carcinoma with capsular invasion, portal vein
tumor thrombi and patients’ clinical outcome. Jpn J Clin Oncol.
44:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong ZZ, Yao M, Wang L, Wu W, Gu X and Yao
DF: Hypoxia-inducible factor-1alpha: Molecular-targeted therapy for
hepatocellular carcinoma. Mini Rev Med Chem. 13:1295–1304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wong CC, Kai AK and Ng IO: The impact of
hypoxia in hepatocellular carcinoma metastasis. Front Med. 8:33–41.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He C, Sun XP, Qiao H, Jiang X, Wang D, Jin
X, Dong X, Wang J, Jiang H and Sun X: Downregulating
hypoxia-inducible factor-2α improves the efficacy of doxorubicin in
the treatment of hepatocellular carcinoma. Cancer Sci. 103:528–534.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin CP, Liu CR, Lee CN, Chan TS and Liu
HE: Targeting c-Myc as a novel approach for hepatocellular
carcinoma. World J Hepatol. 2:16–20. 2010.PubMed/NCBI
|
|
28
|
Fang Y, Huang B, Liang Q, Li H and Huang
C: Clinical significance of c-myc oncogene amplification in primary
hepatocellular carcinoma by interphase fluorescence in situ
hybridization. Zhonghua Bing Li Xue Za Zhi. 30:180–182. 2001.(In
Chinese). PubMed/NCBI
|
|
29
|
Li P, Cao Y, Li Y, Zhou L, Liu X and Geng
M: Expression of Wnt-5a and β-catenin in primary hepatocellular
carcinoma. Int J Clin Exp Pathol. 7:3190–3195. 2014.PubMed/NCBI
|
|
30
|
Qu B, Liu BR, Du YJ, Chen J, Cheng YQ, Xu
W and Wang XH: Wnt/β-catenin signaling pathway may regulate the
expression of angiogenic growth factors in hepatocellular
carcinoma. Oncol Lett. 7:1175–1178. 2014.PubMed/NCBI
|
|
31
|
Yoshida T, Hashimura M, Mastumoto T, Tazo
Y, Inoue H, Kuwata T and Saegusa M: Transcriptional upregulation of
HIF-1α by NF-κB/p65 and its associations with β-catenin/p300
complexes in endometrial carcinoma cells. Lab Invest. 93:1184–1193.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jeong JK and Park SY: HIF-1α-induced
β-catenin activation prevents prion-mediated neurotoxicity. Int J
Mol Med. 32:931–937. 2013.PubMed/NCBI
|
|
33
|
Yang YY, Lee PC, Huang YT, Lee WP, Kuo YJ,
Lee KC, Hsieh YC, Lee TY and Lin HC: Involvement of the HIF-1α and
Wnt/β-catenin pathways in the protective effects of losartan on
fatty liver graft with ischaemia/reperfusion injury. Clin Sci
(Lond). 126:163–174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi H, Chun YS, Kim TY and Park JW:
HIF-2alpha enhances beta-catenin/TCF-driven transcription by
interacting with beta-catenin. Cancer Res. 70:10101–10111. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Q, Bai X, Chen W, Ma T, Hu Q, Liang
C, Xie S, Chen C, Hu L, Xu S, et al: Wnt/β-catenin signaling
enhances hypoxia-induced epithelial-mesenchymal transition in
hepatocellular carcinoma via crosstalk with hif-1α signaling.
Carcinogenesis. 34:962–973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee SH, Kim MH and Han HJ: Arachidonic
acid potentiates hypoxia-induced VEGF expression in mouse embryonic
stem cells: Involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol
Cell Physiol. 297:C207–C216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu L, Huang X, Li L, Huang H, Xu R and
Luyten W: Insights on biology and pathology of HIF-1α/-2α,
TGFβ/BMP, Wnt/β-catenin, and NF-κB pathways in osteoarthritis. Curr
Pharm Des. 18:3293–3312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi H, Chun YS, Kim TY and Park JW:
HIF-2alpha enhances beta-catenin/TCF-driven transcription by
interacting with beta-catenin. Cancer Res. 70:10101–10111. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park YK, Park B, Lee S, Choi K, Moon Y and
Park H: Hypoxia-inducible factor-2α-dependent hypoxic induction of
Wnt10b expression in adipogenic cells. J Biol Chem.
288:26311–26322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li YJ, Wei ZM, Meng YX and Ji XR:
Beta-catenin up-regulates the expression of cyclinD1, c-myc and
MMP-7 in human pancreatic cancer: Relationships with carcinogenesis
and metastasis. World J Gastroenterol. 11:2117–2123. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Anna CH, Iida M, Sills RC and Devereux TR:
Expression of potential beta-catenin targets, cyclin D1, c-Jun,
c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular
neoplasms from B6C3F1 mice. Toxicol Appl Pharmacol. 190:135–145.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shiina H, Igawa M, Shigeno K, Terashima M,
Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ and Dahiya R:
Beta-catenin mutations correlate with over expression of C-myc and
cyclin D1 Genes in bladder cancer. J Urol. 168:2220–2226. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch
W, Wang R, Green DR, Tessarollo L, Casellas R, et al: c-Myc is a
universal amplifier of expressed genes in lymphocytes and embryonic
stem cells. Cell. 151:68–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin CY, Lovén J, Rahl PB, Paranal RM,
Burge CB, Bradner JE, Lee TI and Young RA: Transcriptional
amplification in tumor cells with elevated c-Myc. Cell. 151:56–67.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rahl PB, Lin CY, Seila AC, Flynn RA,
McCuine S, Burge CB, Sharp PA and Young RA: c-Myc regulates
transcriptional pause release. Cell. 141:432–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
